On January 28, 2025, OS Therapies Incorporated (NYSE: OSTX) announced it had entered into an Asset Purchase Agreement with Ayala Pharmaceuticals, Inc. Under this agreement, OS Therapies will acquire all HER2 and Listeria monocytogenes (Lm) related intellectual property (IP) from Ayala. The acquisition includes two Investigational New Drug filings with the US Food & Drug Administration (FDA) for ADXS-503 and ADXS-504, targeting Non-Small Cell Lung Cancer (NSCLC) and Prostate Cancer respectively.
As per the terms of the agreement, OS Therapies will pay an aggregate purchase price of $8 million. This will include $0.5 million in cash and $7.5 million worth of OS Therapies’ common shares. The company has also agreed to eliminate certain milestone payments and reduce future royalty obligations tied to OST-HER2 for osteosarcoma and other HER2-related indications.
Karim Galzahr was also elected to OS Therapies’ Board of Directors on January 28, 2025. With significant experience in finance, M&A, and asset management across technology and medical technology sectors, Galzahr’s appointment brings valuable expertise to the Company’s leadership.
The acquisition highlights OS Therapies’ strategic growth initiatives and commitment to advancing its immunotherapies and targeted drug conjugates for cancer treatment. By strengthening its intellectual property portfolio and financial position, the company aims to bolster its market presence and further its mission of transforming cancer care globally.
The full press release regarding the acquisition, appointment of Mr. Galzahr, and notable clinical data conclusions related to the lung cancer asset can be found on OS Therapies’ website and social media platforms.
Cautionary Note Regarding Forward-Looking Statements: This report contains forward-looking statements that involve risks and uncertainties, which could cause actual results to differ materially from future expectations expressed or implied in such statements. OS Therapies urges caution as these statements are based on current expectations and various assumptions and are subject to changes beyond the Company’s control.
Please refer to the SEC filings for further details and updates on OS Therapies’ strategic developments and financial performance. For more information, visit the company’s website or get in touch with their Investor Relations team.
This article is based on the 8-K SEC filing dated January 28, 2025.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read OS Therapies’s 8K filing here.
About OS Therapies
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
See Also
- Five stocks we like better than OS Therapies
- Dividend Capture Strategy: What You Need to Know
- 3 Steel Stocks Soaring After Tariff Announcements
- What Investors Need to Know About Upcoming IPOs
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- Which Wall Street Analysts are the Most Accurate?
- Why Salesforce Stock Could Be at Fresh Highs by February
